LluÃs Espinosa, MD from IMIM-Hospital del Mar and CIBERONC speaks about Optimising Metastatic Melanoma Therapy By Combining Two Treatments.Link to Article:https://www.healtheuropa.eu/optimising-metastatic-melanoma-therapy-by-combining-two-treatments/109884/Combining chemotherapy with BRAF oncogene inhibitors may be the most effective treatment for metastatic melanoma, according to a new study.Researchers from the Hospital del Mar Medical Research Institute, Hospital del Mar, CIBER Cancer, and the Bellvitge Medical Research Institute collaborated on the study, which found that a combination of chemotherapy and BRAF oncogene inhibitors can successfully cure metastatic melanoma.The findings were reported in the Oncogene journal.Metastatic melanoma is the top cause of skin cancer mortality worldwide; now, breakthrough research might…
Author: Editor
Tony Kurian, MD, Oncology Fellow at H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract – Using tissue microarray to detect inflammasome signaling components that contribute to the pathogenesis of myelodysplastic syndrome.Link to Abstract:https://meetinglibrary.asco.org/record/196283/abstractBackground:Abnormal maturation, inefficient hematopoiesis, cytopenia, and the development of acute myeloid leukemia are all symptoms of myelodysplastic syndromes (MDS). The etiology of MDS is complex, and it may be connected to innate immunological activation that converges on the NLRP3 inflammasome to cause pyroptosis, a caspase-1-dependent cell death. Both cell-extrinsic stimuli, such as S100A9, the TLR4, and CD33 ligand, and cell-intrinsic danger signals,…
Yeonjoo Choi, MD from The Catholic University of Korea Incheon St. Mary’s Hospital speaks about T-cell Agonists In Cancer Immunotherapy.Link to Article:https://jitc.bmj.com/content/8/2/e000966Article:Cancer cells have the ability to avoid the body’s immune system. Immune checkpoint drugs, on the other hand, can stop this evasion and boost T cell antitumor activity. Targeting costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator, and glucocorticoid-induced tumor necrosis factor receptor, are further methods for boosting antitumor T-cell activity. CD40 also targets the regulation of antigen-presenting cell activation, which eventually leads to T-cell activation. These costimulatory molecule antagonists have…
Sarah E. S. Leary, MD, Associate Professor, Center for Clinical and Translational Research, at the Seattle Children’s Hospital Research Foundation speaks about Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma.Link to Abstract:https://jamanetwork.com/journals/jamaoncology/article-abstract/2782033Points to RememberQuestion Is it possible to increase survival in children with high-risk medulloblastoma by using carboplatin during radiotherapy or isotretinoin during maintenance chemotherapy?FindingsIsotretinoin did not enhance survival in this randomized clinical study including 261 children with medulloblastoma. Only children with high-risk group 3 medulloblastoma benefitted from the inclusion of carboplatin after radiation, with survival increasing from 54% to 73%.MeaningBecause the inclusion of carboplatin during radiotherapy is…
Oliver Dorigo, MD, Ph.D., Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer.Link to Article:https://www.yahoo.com/now/imv-announces-final-topline-results-111100436.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALAhDmoRF2NQvBiTDvQ4PVTifWqPcfjrSLjPgkGwBSifYnlxQ066nMYSXTn7dGZIfkbLMbYWL8rJK3x3WQBAv2prfA712B5Dz6xDI8k1feWNneQ1P9oMfq1Vsp08EkMUFELt9bgR8-a63hmRM0VjHwB_FXsokCNrn7tB6yQRo10aLink to Study:https://www.clinicaltrials.gov/ct2/show/NCT02785250?cond=ovarian+cancer&spons=IMV&draw=2&rank=1IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The specifics of these translational assessments have been submitted for presentation at forthcoming scientific events.The DeCidE1 ResearchThe “DeCidE1” trial compared the…
Jubilee Brown, MD from the Levine Cancer Institute, and Division of Gynecologic Oncology, Atrium Health speaks about Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/33001143/Abstract:Importance:Endometrial tumors with faulty mismatch mutation repair systems may be more susceptible to anti-programmed death 1 (PD-1) treatments. Dostarlimab (TSR-042) is an anti-PD-1 antibody that binds to the PD-1 receptor with a high affinity.Objective:Dostarlimab’s anticancer efficacy and safety in patients with defective mismatch repair endometrial cancer were investigated.Participants, setting, and design:On March 7, 2016,…
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Abstract – #e21047 – Myocarditis as a rare, yet serious adverse event associated with immune checkpoint inhibitors in patients with non-small cell lung cancer: Case series from a large community-based cancer center.Link to Abstract:https://meetinglibrary.asco.org/record/200926/abstractBackground:Immune checkpoint inhibitors (ICI) may cause immune-related adverse effects in patients with lung cancer and other malignancies (irAE). Pneumonitis, colitis, hepatitis, and myocarditis/pericarditis can all manifest with varying degrees of severity and single- or multi-organ involvement. Myocarditis occurs in 0.06 percent to 2.4 percent of the population and is associated with a significant death rate (25…
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Poster – #9105 – Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.Link to Poster:https://meetinglibrary.asco.org/record/200547/abstractBackground:Immune checkpoint inhibitor (ICI) therapy has become a standard of care for patients with non-small cell lung cancer (NSCLC). However, not all patients (pts) benefit with ICI, with a percentage reporting increased tumor development. Hyperprogression (HP) is a term used to describe faster tumor development on ICI along with the deteriorating clinical state. MDM2/MDM4 amplifications, EGFR alterations, and STK11/LKB1 mutations are some of the gene changes that have been…
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Abstracts – #9105 – Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors, #e21047 – Myocarditis as a rare, yet serious adverse event associated with immune checkpoint inhibitors in patients with non-small cell lung cancer: Case series from a large community-based cancer center, and #e21121 – Feasibility of RECIST-based real-world tumor response assessment in metastatic non-small cell lung cancer patients.Link to Poster #9105:https://meetinglibrary.asco.org/record/200547/abstractLink to Abstract #e21047:https://meetinglibrary.asco.org/record/200926/abstractLink to Abstract #e21121:https://meetinglibrary.asco.org/record/201064/abstract#9105 Background:Immune checkpoint inhibitor (ICI) therapy has become a standard of care for patients with…
Somedeb Ball, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.Link to Abstract:https://meetinglibrary.asco.org/record/195837/abstractBackground:In individuals with acute myeloid leukemia, extramedullary (EM) involvement, such as myeloid sarcoma (MS) and leukemia cutis (LC), is uncommon (AML). The mutational landscape of EM-AML is unknown, as is the concordance of sequencing data from EM vs. non-EM sites (blood or bone marrow) and the possibility of customized targeted treatment in this patient population.Methods:Clinical and genomic data on EM-AML patients treated at Moffitt Cancer Center, Memorial Healthcare System, and University…
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Abstract – #e21121 – Feasibility of RECIST-based real-world tumor response assessment in metastatic non-small cell lung cancer patients.Link to Abstract:https://meetinglibrary.asco.org/record/201064/abstractBackground:The Response Evaluation Criteria in Solid Tumors (RECIST) is commonly used to assess treatment response to anti-cancer medicines for advanced lung cancer, however, it is not widely used in real-world settings. With real-world evidence increasingly being used to back promising treatments, this study looked into the feasibility of assessing real-world lung cancer response using RECIST-based measurement of lesions on archived radiologic films and comparing it to treatment response based on…
Philippe Spiess, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract – Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.Link to Abstract:https://meetinglibrary.asco.org/record/197709/abstractBackground:We used CGP to look for probable genetic changes between tumor types because the clinical symptoms, disease course, and treatment choices for pSCC varied.Methods:1,741 clinically advanced pSCCs underwent hybrid capture-based CGP to evaluate all classes of genomic alterations, including 230 penile (penSCC), 17 male urethral (murthSCC), 125 male anal (manSCC), 7 female urethral (furthSCC), 263 vulvar (vulSCC), 822 cervical (crvSCC), and 277 female…
Gregory T. Kennedy, MD from Penn Medicine speaks about Targeted Intraoperative Molecular Imaging for Localizing Nonpalpable Tumors and Quantifying Resection Margin Distances.Link to Abstract:https://jamanetwork.com/journals/jamasurgery/article-abstract/2783502Points to Remember:A Question – Can intraoperative molecular imaging correctly predict resection margin adequacy and locate nonpalpable, visually occult tumors?Conclusions -Intraoperative molecular imaging identified 83 percent of nonpalpable, nonvisible lesions in this nonrandomized open-label trial of 40 adults with a T1 pulmonary lesion radiographically suspicious for a nonpalpable cancer, and intraoperative molecular imaging–calculated margins were nearly identical to those reported on final pathology.Defined -Intraoperative molecular imaging can enhance surgical care of nonpalpable tumors across the area of…
Gregory T. Kennedy, MD from Penn Medicine speaks about Targeted Intraoperative Molecular Imaging for Localizing Nonpalpable Tumors and Quantifying Resection Margin Distances.Link to Abstract:https://jamanetwork.com/journals/jamasurgery/article-abstract/2783502Points to Remember:A Question – Can intraoperative molecular imaging correctly predict resection margin adequacy and locate nonpalpable, visually occult tumors?Conclusions -Intraoperative molecular imaging identified 83 percent of nonpalpable, nonvisible lesions in this nonrandomized open-label trial of 40 adults with a T1 pulmonary lesion radiographically suspicious for a nonpalpable cancer, and intraoperative molecular imaging–calculated margins were nearly identical to those reported on final pathology.Defined -Intraoperative molecular imaging can enhance surgical care of nonpalpable tumors across the area of…
Kilian E. Salerno, MD, vice chair of the guideline task force and a radiation oncologist at the National Cancer Institute speaks about ASTRO Issues Clinical Guideline On Radiation Therapy For Soft Tissue Sarcoma In Adults.Link to Article:https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2021/ASTRO-issues-clinical-guideline-on-radiation-theraLink to ASTRO Guidlines:https://www.practicalradonc.org/article/S1879-8500(21)00118-1/fulltextThe American Society for Radiation Oncology (ASTRO) has released a new clinical guideline on the use of radiation treatment to treat adult patients with soft tissue sarcoma (STS). Patients with localized, operable STS of the trunk (i.e., chest wall, abdominal wall) and extremities (i.e., arms, legs) should receive optimal radiation dosage, methods, and treatment planning, with an emphasis on maintaining long-term…
Kilian E. Salerno, MD, vice chair of the guideline task force and a radiation oncologist at the National Cancer Institute speaks about ASTRO Issues Clinical Guideline On Radiation Therapy For Soft Tissue Sarcoma In Adults.Link to Article:https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2021/ASTRO-issues-clinical-guideline-on-radiation-theraLink to ASTRO Guidlines:https://www.practicalradonc.org/article/S1879-8500(21)00118-1/fulltextThe American Society for Radiation Oncology (ASTRO) has released a new clinical guideline on the use of radiation treatment to treat adult patients with soft tissue sarcoma (STS). Patients with localized, operable STS of the trunk (i.e., chest wall, abdominal wall) and extremities (i.e., arms, legs) should receive optimal radiation dosage, methods, and treatment planning, with an emphasis on maintaining long-term…
Jennifer Linehan, M.D., Associate Professor of Urology and Urologic Oncology at Saint John’s Cancer Institute, Investigator of the OLYMPUS trial speaks about LBA02-10 Long-term Recurrence Free Survival Following UGN-101 Treatment For Low-grade Upper Tract Urothelial Carcinoma.Link to Abstract:https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002149.10A summary -OBJECTIVE AND INTRODUCTION:In individuals with tiny, unifocal tumors, radical nephroureterectomy (RNU) or nephron-sparing endoscopic surgery is the standard therapy for low-grade upper tract urothelial carcinoma (LG UTUC) affecting the renal pelvis and calyces. Patients who had a complete response (CR) after induction therapy with UGN-101 (JELMYTO), a mitomycin-containing reverse thermal gel, had an estimated response durability of 84 percent at 12…
Jennifer Linehan, M.D., Associate Professor of Urology and Urologic Oncology at Saint John’s Cancer Institute, Investigator of the OLYMPUS trial speaks about LBA02-10 Long-term Recurrence Free Survival Following UGN-101 Treatment For Low-grade Upper Tract Urothelial Carcinoma.Link to Abstract:https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002149.10A summary -OBJECTIVE AND INTRODUCTION:In individuals with tiny, unifocal tumors, radical nephroureterectomy (RNU) or nephron-sparing endoscopic surgery is the standard therapy for low-grade upper tract urothelial carcinoma (LG UTUC) affecting the renal pelvis and calyces. Patients who had a complete response (CR) after induction therapy with UGN-101 (JELMYTO), a mitomycin-containing reverse thermal gel, had an estimated response durability of 84 percent at 12…
Jason Sicklick, MD, Surgical Oncologist, Associate Professor of Surgery at UC San Diego Health speaks about Establishment of Patient-derived Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumor Models For Predicting Therapeutic Response.Link to Abstract:https://clincancerres.aacrjournals.org/content/early/2021/08/20/1078-0432.CCR-21-2092.abstracta summary -Purpose:GIST is the most prevalent gastrointestinal sarcoma, with mutant succinate dehydrogenase (SDH) subunits (A-D) accounting for fewer than 7.5 percent (i.e. 150-200 new cases per year) of new cases in the United States. SDH-mutant GISTs, unlike GISTs with KIT or PDGFRA mutations, afflict teenagers and young adults, often metastasis, and are resistant to tyrosine kinase inhibitors (TKIs). Because there are no human models for any SDH-mutant tumors, including…
Jason Sicklick, MD, Surgical Oncologist, Associate Professor of Surgery at UC San Diego Health speaks about Establishment of Patient-derived Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumor Models For Predicting Therapeutic Response.Link to Abstract:https://clincancerres.aacrjournals.org/content/early/2021/08/20/1078-0432.CCR-21-2092.abstracta summary -Purpose:GIST is the most prevalent gastrointestinal sarcoma, with mutant succinate dehydrogenase (SDH) subunits (A-D) accounting for fewer than 7.5 percent (i.e. 150-200 new cases per year) of new cases in the United States. SDH-mutant GISTs, unlike GISTs with KIT or PDGFRA mutations, afflict teenagers and young adults, often metastasis, and are resistant to tyrosine kinase inhibitors (TKIs). Because there are no human models for any SDH-mutant tumors, including…
Jason Sicklick, MD, Surgical Oncologist, Associate Professor of Surgery at UC San Diego Health speaks about Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity.Link to Abstract:https://clincancerres.aacrjournals.org/content/early/2021/07/28/1078-0432.CCR-21-1221.abstractAbstract – Goals:GISTs (gastrointestinal stromal tumors) are tumors that develop in various parts of the stomach and are caused by a variety of mutations (most often in KIT, PDGFRA, and SDHx). The anatomic location of gastric GIST is thought to be linked to different genomic profiles and driving mutations.Design of Experiments:In the National Cancer Database (NCDB), we evaluated KIT versus non-KIT status with tumor site in 2,418…
Jason Sicklick, MD, Surgical Oncologist, Associate Professor of Surgery at UC San Diego Health speaks about Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity.Link to Abstract:https://clincancerres.aacrjournals.org/content/early/2021/07/28/1078-0432.CCR-21-1221.abstractAbstract – Goals:GISTs (gastrointestinal stromal tumors) are tumors that develop in various parts of the stomach and are caused by a variety of mutations (most often in KIT, PDGFRA, and SDHx). The anatomic location of gastric GIST is thought to be linked to different genomic profiles and driving mutations.Design of Experiments:In the National Cancer Database (NCDB), we evaluated KIT versus non-KIT status with tumor site in 2,418…
Ajay Goel, Ph.D., AGAF, chair of City of Hope’s Department of Molecular Diagnostics and Experimental Therapeutics speaks about Assessment of the Diagnostic Efficiency of a Liquid Biopsy Assay for Early Detection of Gastric Cancer.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34427680/Summary -Significance:Noninvasive early-stage disease diagnosis is an important method for lowering gastric cancer (GC)-related patient death.Goal:Using a thorough biomarker discovery strategy with retrospective and prospective validation, create a new, noninvasive microRNA (miRNA)-based signature for the early identification of GC.Participants, environment, and layout:This diagnostic investigation was carried out in four steps, utilizing publicly accessible genome sequences and tissue samples from patients at a Japanese university medical…
Ajay Goel, Ph.D., AGAF, chair of City of Hope’s Department of Molecular Diagnostics and Experimental Therapeutics speaks about Assessment of the Diagnostic Efficiency of a Liquid Biopsy Assay for Early Detection of Gastric Cancer.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34427680/Summary -Significance:Noninvasive early-stage disease diagnosis is an important method for lowering gastric cancer (GC)-related patient death.Goal:Using a thorough biomarker discovery strategy with retrospective and prospective validation, create a new, noninvasive microRNA (miRNA)-based signature for the early identification of GC.Participants, environment, and layout:This diagnostic investigation was carried out in four steps, utilizing publicly accessible genome sequences and tissue samples from patients at a Japanese university medical…
Miranda Gogishvili, MD High Technology Medical Center, University Clinic speaks about Phase 3 Trial of Libtayo® (Cemiplamab-RWLC) Combined With Chemotherapy Stopped Early Due to Significant Improvement In Overall Survival In Patients With First-line Advanced Non-small Cell Lung Cancer.Link to Article:https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-libtayor-cemiplimab-rwlc-combined-chemotherapyThe combination of Libtayo and chemotherapy enhanced median overall survival from 13 to 22 months, lowering the chance of mortality by 29%.Patients with locally progressed and metastatic disease with squamous or non-squamous histology and all levels of PD-L1 expression were included in the study.Libtayo has now been shown to enhance overall survival in first-line advanced non-small cell lung cancer patients either…
Miranda Gogishvili, MD High Technology Medical Center, University Clinic speaks about Phase 3 Trial of Libtayo® (Cemiplamab-RWLC) Combined With Chemotherapy Stopped Early Due to Significant Improvement In Overall Survival In Patients With First-line Advanced Non-small Cell Lung Cancer.Link to Article:https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-libtayor-cemiplimab-rwlc-combined-chemotherapyThe combination of Libtayo and chemotherapy enhanced median overall survival from 13 to 22 months, lowering the chance of mortality by 29%.Patients with locally progressed and metastatic disease with squamous or non-squamous histology and all levels of PD-L1 expression were included in the study.Libtayo has now been shown to enhance overall survival in first-line advanced non-small cell lung cancer patients either…
Wenxin (Vincent) Xu, MD from Dana-Farber Cancer Institute speaks about Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34124786/Abstract:The goal of our research was to see if there were any inequalities in clinical trial participation for certain patient categories. For each FDA-approved medication approved between January 1, 2006, and June 30, 2020, we searched the FDA database and collected phase-III clinical trial data from MEDLINE. We looked at the inclusion and exclusion criteria, as well as participation by gender, ethnic group, performance score, HBV and HCV positive, HIV,…
Wenxin (Vincent) Xu, MD from Dana-Farber Cancer Institute speaks about Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34124786/Abstract:The goal of our research was to see if there were any inequalities in clinical trial participation for certain patient categories. For each FDA-approved medication approved between January 1, 2006, and June 30, 2020, we searched the FDA database and collected phase-III clinical trial data from MEDLINE. We looked at the inclusion and exclusion criteria, as well as participation by gender, ethnic group, performance score, HBV and HCV positive, HIV,…
Hosts Jack West & Charu Aggarwal speak with immunotherapy expert Dr. Patrick Forde about unique advantages of the pre-operative platform for systemic therapy, especially immunotherapy, in early stage cancer & pathologic response assessment from surgery.
Sajeve Thomas, MD, an oncologist and hematologist at the Orlando Health Cancer Institute speaks about Using A Patient’s Own Tumor Cells As Ammunition To Fight Their Cancer.Link to Article:http://oh.multimedia-newsroom.com/index.php/2021/08/04/using-a-patients-own-tumor-cells-as-ammunition-to-fight-their-cancer/Intent:Patients with advanced (metastatic or unresectable) melanoma who do not respond to immune checkpoint inhibitors or targeted treatments have limited therapeutic choices. In metastatic melanoma, adoptive cell treatment with tumor-infiltrating lymphocytes has shown to be effective. Lifileucel is a tumor-infiltrating lymphocyte product that is autologous and produced centrally.Methodologies:In patients with metastatic melanoma who had previously been treated with checkpoint inhibitors and BRAF 6 MEK targeted therapies, we undertook a phase II open-label,…
Sajeve Thomas, MD, an oncologist and hematologist at the Orlando Health Cancer Institute speaks about Using A Patient’s Own Tumor Cells As Ammunition To Fight Their Cancer.Link to Article:http://oh.multimedia-newsroom.com/index.php/2021/08/04/using-a-patients-own-tumor-cells-as-ammunition-to-fight-their-cancer/Intent:Patients with advanced (metastatic or unresectable) melanoma who do not respond to immune checkpoint inhibitors or targeted treatments have limited therapeutic choices. In metastatic melanoma, adoptive cell treatment with tumor-infiltrating lymphocytes has shown to be effective. Lifileucel is a tumor-infiltrating lymphocyte product that is autologous and produced centrally.Methodologies:In patients with metastatic melanoma who had previously been treated with checkpoint inhibitors and BRAF 6 MEK targeted therapies, we undertook a phase II open-label,…
Kana Wu, M.D., Ph.D., Principal Research Scientist in the Department of Nutrition at Harvard T. H. Chan School of Public Health, Member of the Dana-Farber/Harvard Cancer Center (DF/HCC, program affiliation: Cancer Epidemiology and Gastrointestinal Malignancies), Member of the Working Group for the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 114 (Red Meat and Processed Meat) Speaks about the Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red Meat.Link to Article:https://www.cancer.gov/news-events/cancer-currents-blog/2021/red-meat-colorectal-cancer-genetic-signatureA diet heavy in red and processed meats has been related to colorectal cancer in several studies, but it’s unclear how eating cheeseburgers, hot…
Kana Wu, M.D., Ph.D., Principal Research Scientist in the Department of Nutrition at Harvard T. H. Chan School of Public Health, Member of the Dana-Farber/Harvard Cancer Center (DF/HCC, program affiliation: Cancer Epidemiology and Gastrointestinal Malignancies), Member of the Working Group for the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 114 (Red Meat and Processed Meat) Speaks about the Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red Meat.Link to Article:https://www.cancer.gov/news-events/cancer-currents-blog/2021/red-meat-colorectal-cancer-genetic-signatureA diet heavy in red and processed meats has been related to colorectal cancer in several studies, but it’s unclear how eating cheeseburgers, hot…
Eric Jonasch, MD, principal investigator of Study 004 and professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center speaks about FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREGâ„¢ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors.Link to Article:https://www.merck.com/news/fda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%CE%B1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease/WELIREG is the first HIF-2 inhibitor treatment to receive FDA approval in the United States. WELIREG inhibits transcription and expression of HIF-2 target genes linked with cellular proliferation, angiogenesis, and tumor development as an HIF-2 inhibitor.A boxed warning on the WELIREG label states that exposure to…
Eric Jonasch, MD, principal investigator of Study 004 and professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center speaks about FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREGâ„¢ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors.Link to Article:https://www.merck.com/news/fda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%CE%B1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease/WELIREG is the first HIF-2 inhibitor treatment to receive FDA approval in the United States. WELIREG inhibits transcription and expression of HIF-2 target genes linked with cellular proliferation, angiogenesis, and tumor development as an HIF-2 inhibitor.A boxed warning on the WELIREG label states that exposure to…
Laura Esserman, MD, MBA, Professor of Surgery and Radiology is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center’s multidisciplinary programs speaks about The Wisdom Study – “How often should women screen for breast cancer?â€.Link to Article:https://www.thewisdomstudy.org/As it approaches the 30,000 woman mark, nationwide research investigating a customized approach to breast cancer screening and risk assessment has begun a fresh push to diversify its participants.WISDOM…
Laura Esserman, MD, MBA, Professor of Surgery and Radiology is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center’s multidisciplinary programs speaks about The Wisdom Study – “How often should women screen for breast cancer?â€.Link to Article:https://www.thewisdomstudy.org/As it approaches the 30,000 woman mark, nationwide research investigating a customized approach to breast cancer screening and risk assessment has begun a fresh push to diversify its participants.WISDOM…
In this tutorial, you will learn how to upload a video.
In this tutorial, you will learn how to create an article.
In this tutorial, you will learn how to set up your user account and channel.
Howard ‘Jack’ West, MD, Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology and; Therapeutics Research at the City of Hope speaks about ASCO 2021 Highlights in Lung Cancer.Link to Abstract 8500- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).https://meetinglibrary.asco.org/record/195950/abstractLink to Abstract 8503 – Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).https://meetinglibrary.asco.org/record/195951/abstractLink to Abstract 9001 -…
David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College speaks about ASCO 2021 Highlights in Colorectal Cancer and Gastrointestinal Cancer.Link to Abstract 4000 – ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).https://meetinglibrary.asco.org/record/195933/abstractLink to Abstract LBA4001 – Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.https://meetinglibrary.asco.org/record/195919/abstractLink to Abstract 4002 – First-line (1L)…